Bevacizumab for Retinopathy of Prematurity

Bevacizumab for retinopathy of prematurity.

Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.

Retinopathy of prematurity (ROP), a disease of abnormal blood vessel proliferation in the retina, is estimated to account for approximately 20% of cases of pediatric blindness worldwide. Guidelines set by the American Academy of Pediatrics, the American Academy of Ophthalmology, and the American Association for Pediatric Ophthalmology and Strabismus outline criteria for the screening and treatm...

Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.

PURPOSE To assess the effect of intravitreal bevacizumab for Type 1 retinopathy of prematurity (ROP) in zone II ROP. METHODS We conducted a randomized clinical trial. Preterm infants with a gestational age less than 34 weeks or birthweight less than 2000 g were examined at 4 weeks chronological age or 31 weeks postmenstrual age (whichever was later). Preterm infants with Zone-II/Stage 2 or 3 ...

Bevacizumab treatment for retinopathy of prematurity in South Africa.

Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of Prematurity

zumab therapy as compared with children undergoing retinal laser coagulation were significantly less myopic at 1 year of follow-up. Although the cause for myopization in children treated for ROP has remained unclear so far, the results of our study are in line with previous investigations in which myopization was more pronounced in children randomized for the more invasive cryotherapy than in t...